Dichloroisoprenaline
Names | |
---|---|
Preferred IUPAC name
Dichloroisoprenaline | |
Systematic IUPAC name
1-(3,4-Dichlorophenyl)-2-[(propan-2-yl)amino]ethan-1-ol | |
Other names
1-(3,4-Dichlorophenyl)-2-(isopropylamino)ethanol Dichlorisoproterenol | |
Identifiers | |
59-61-0 | |
3D model (Jmol) | Interactive image Interactive image |
ChEBI | CHEBI:144234 |
ChEMBL | ChEMBL30816 |
ChemSpider | 5601 (1R) 5324297 (1S) 5601 () |
KEGG | C11772 |
MeSH | Dichloroisoproterenol |
PubChem | 5806 (1R) 6951395 (1S) 5806 () |
| |
| |
Properties | |
C11H15Cl2NO | |
Molar mass | 248.15 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Dichloroisoprenaline (DCI), also known as dichloroisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β1-adrenergic and β2-adrenergic receptors. DCI has low potency and acts as a partial agonist/antagonist at these receptors.[1]
Although DCI was of no clinical value itself, further developments from DCI eventually led to the development of the clinical candidate pronethalol (withdrawn due to carcinogenicity) and subsequently propranolol (the first clinically successful beta blocker).
Dichloroisoprenaline is a racemic mixture of enantiomers.
References
- ↑ W. E. Glover; A. D. M. Greenfield; R. G. Shanks (October 1962). "Effect of dichloroisoprenaline on the peripheral vascular responses to adrenaline in man". Br J Pharmacol Chemother. 19: 235–244. doi:10.1111/j.1476-5381.1962.tb01185.x. PMC 1482134. PMID 13948521.
This article is issued from Wikipedia - version of the 7/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.